Signal active
Bio
Liam Ratcliffe is a General Partner at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Liam joined New Leaf in September 2008.
He is currently on the board of directors of Afferent Pharmaceuticals Inc, Array BioPharma Inc. (ARRY), Calchan Holdings Ltd., Convergence Pharmaceuticals Ltd, and Neuronetics Inc. Liam previously served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development.
Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region (based in Ann Arbor, MI), and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. As Head of Neurosciences, Liam was responsible for the development of several successful late-stage projects and marketed products, including Lyrica, Chantix and Geodon.
Liam began his career in the pharmaceutical industry in a medical marketing role at Roche in South Africa. He received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.
Location
New York, New York, United States, North America
Social
Primary Organization
1986
33
14
12
1001-5000
Biotechnology, Life Science, Health Care, Biopharma
Jobs history
2
Eliem Therapeutics
Board Member
Invalid date - Current
Access Biotechnology
Head of Biotechnology
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Liam Ratcliffe is the Head of Biotechnology at Access Biotechnology, based in New York, New York, United States, North America. With a background in Biotechnology, Liam Ratcliffe has a rich history of leadership and innovation. Liam Ratcliffe studied MD Immunology @ University of Cape Town. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
Dheeraj Jain
Co-Founder & Managing Director
Manoj Mehta
No designation
Ambuj Chaudhary
No designation
Sunil Kumar Singhvi
No designation
Investment portfolio
1
0
Personal investment
1
Annouced Date | Organization Name | Funding Round | Money Raised |
---|---|---|---|
Feb 01, 2021 | Shoopy | Seed Round - Shoopy | 250.0K |
Partner investment
11
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Feb 15, 2019 | Passage Bio | Series A - Passage Bio | New Leaf Venture Partners | 115.5M |
Sep 04, 2019 | Passage Bio | Series B - Passage Bio | New Leaf Venture Partners | 110.0M |
Mar 25, 2021 | Eliem Therapeutics | Series A - Eliem Therapeutics | Access Biotechnology | 80.0M |
May 24, 2021 | Eliem Therapeutics | Series B - Eliem Therapeutics | Access Biotechnology | 60.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.